Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder - Abstract

OBJECTIVE:To determine the pharmacokinetics, safety and tolerability of fesoterodine, and assess the utility of 3-day bladder diaries (exploratory objective) in pediatric subjects with neurogenic detrusor overactivity or idiopathic overactive bladder (OAB).

METHODS: In this 8-week open-label study, subjects (8-17 years, >25 kg) received fesoterodine 4 mg for 4 weeks, then 8 mg for 4 weeks. Blood samples were obtained at weeks 4 and 8.

RESULTS: Of 21 subjects enrolled, 11 had neurogenic detrusor overactivity and 10 had idiopathic OAB; 1 discontinued (personal reasons). Mean age and weight were 13.2 years and 54.0 kg for boys (n = 12) and 13.1 years and 49.2 kg for girls (n = 9). 5-Hydroxy-methyltolterodine plasma concentrations did not differ by diagnosis and were consistent with predictions based on adult data. Treatment-related adverse events (all mild or moderate) included 1 event each of dry mouth, constipation, dry eyes and blurred vision, and 2 events each of nausea and increased post-void residual volume. Three-day bladder diaries proved feasible.

CONCLUSIONS: Oral administration of fesoterodine in pediatric subjects (>25 kg) with idiopathic OAB or neurogenic detrusor overactivity produced steady-state plasma 5-hydroxy-methyltolterodine exposures similar to those in adults. The doses given were well tolerated.

Written by:
Malhotra B, El-Tahtawy A, Wang EQ, Darekar A, Cossons N, Crook TJ, Scholfield D, Reddy P. Are you the author?
Pfizer Inc, 685 3rd Ave, Mail stop 235/09/31, New York, NY 10017, USA.

Reference: J Pediatr Urol. 2012 Mar 12. Epub ahead of print.
doi: 10.1016/j.jpurol.2012.02.008

PubMed Abstract
PMID: 22417681